Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of sutacimig for prophylaxis in glanzmann thrombasthenia: A trial in progress

View Full Paper
Ask AI
Bookmark
Share

Authors

PSPaul SaultierFXFrederico XavierAAAndrea Artoni

Discussion

Loading...

Member takes

Overview

Phase 2 trial evaluates safety and pharmacokinetics of sutacimig in glanzmann thrombasthenia, highlighting its potential as prophylaxis.

Key Points

  • To investigate the pharmacokinetics, pharmacodynamics, safety, tolerability, and preliminary efficacy of sutacimig in glanzmann thrombasthenia.
  • Open-label study assessing sutacimig in glanzmann thrombasthenia.
  • Single and multiple ascending dose studies completed.
  • Ongoing long-term extension study evaluating bleeding frequency and severity.
  • Participants aged 18-67 years with≥2 bleeding events weekly eligible for study.
  • Assessing annualized bleeding rates and treated bleeding rates.
  • Evaluating safety and tolerability measures.
  • Preliminary efficacy outcomes suggest potential for improved management.

Cite This Study

Saultier et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e323https://doi.org/10.1182/blood-2025-8232
View Full Paper
Ask AI
Bookmark
Share